Symyx Technologies
| Company type | Public |
|---|---|
| Industry | Scientific research informatics and automation |
| Founded | 1994 |
| Founder | Dr. Alejandro Zaffaroni, Dr. Peter G. Schultz |
| Fate | Software division merged with Accelrys, Inc. in 2010; laboratory robotics division spun off as Freeslate, Inc. in 2010 |
| Products | Enterprise Laboratory Notebooks, combinatorial chemistry software, laboratory robotics |
Symyx Technologies, Inc. was a company focused on informatics and automation solutions tailored for scientific research, offering products such as Enterprise Laboratory Notebooks and software for combinatorial chemistry. In 2010, its software division merged with Accelrys, Inc., which subsequently became part of Dassault Systèmes in 2014. Meanwhile, Symyx’s laboratory robotics segment was separated into an independent entity named Freeslate, Inc. that same year.
Products
Symyx engineered rapid combinatorial technologies by integrating proprietary instruments, software applications, and methodologies designed to swiftly create and evaluate thousands of distinct materials. This approach significantly expedited the discovery process in sectors including life sciences, chemicals, and electronics, achieving throughput hundreds to thousands of times greater than conventional techniques.
History
Established in 1994 by Dr. Alejandro Zaffaroni and Dr. Peter G. Schultz, Symyx built upon the pioneering high-throughput combinatorial research initially developed at Affymax and Affymetrix. Dr. Eric McFarland from UCSB was appointed as the founding director. The company screened close to one million materials annually, identifying viable candidates for commercial use in fields such as X-ray storage phosphors, polymers for DNA research, and catalysts applied in pharmaceuticals and plastics manufacturing.
In 2004, Symyx expanded by acquiring Intellichem, a firm specializing in electronic laboratory notebooks (ELNs). Three years later, in 2007, it purchased MDL Information Systems, an R&D informatics provider with a history dating back to 1978 in computer-aided drug design. This acquisition included the CDC-NIOSH Registry of Toxic Effects of Chemical Substances (RTECS), a critical toxicity database containing roughly 170,000 records as of 2012. In 2008, Symyx divested its non-RTECS occupational health and safety assets to ChemAdvisor, Inc., while continuing to develop its enterprise ELN platform that supports diverse scientific disciplines.
The year 2010 marked the spin-off of Symyx’s laboratory robotics unit into Freeslate, which concentrated on automating high-throughput chemical research processes. Concurrently, the remaining software operations merged with Accelrys through an all-stock deal, creating a combined entity that broadened its footprint in the scientific software market. Accelrys was later integrated into Dassault Systèmes in 2014, which introduced the BIOVIA brand to address global scientific R&D needs.
This progression illustrates Symyx’s strategic focus on innovation within automated materials discovery and informatics technologies, leveraging acquisitions and corporate restructuring to strengthen its competitive position and expand worldwide presence.
Business model considerations
Symyx’s core emphasis was on combinatorial chemistry applications beyond biotechnology, initially providing contract research services to major chemical companies with agreements ranging from $0.5 million up to $200 million. Early partnerships with smaller clients paved the way for significant contracts such as those with Exxon, followed by an expansion into equipment sales.
However, each contract demanded bespoke tool development and recruitment of specialized personnel due to varying research requirements across clients, which constrained scalability. This operational complexity contributed to Symyx’s eventual decline despite possessing a portfolio exceeding 500 patents. Competitors like Intermolecular licensed some of Symyx’s patents related to electronic materials and continue advancing associated technologies.